Skip to main content
Evidence Snapshot

Nischarin

CHEMBL5221 SINGLE PROTEIN Rattus norvegicus
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:28Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5221
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Nischarin as ChEMBL target CHEMBL5221, mapped to UniProt Q4G017. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Nischarin
SINGLE PROTEIN · Rattus norvegicus
As of 2026-09-13
ChEMBL target ID
CHEMBL5221
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q4G017
Nischarin
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Nischarin matters

As of 2026-09-13

Nischarin is reviewed as Nischarin (UniProt Q4G017); the current evidence base includes 6 approved drugs, 201 compounds, and 21 assays, with lead potency reaching pChEMBL 10.5.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 6 approved drugs, 201 compounds, and 21 assays for this target. The dominant activity type is KI. CHEMBL360803 is the current potency anchor at pChEMBL 10.5.

Use CHEMBL360803 as the tractability anchor when discussing potency (pChEMBL 10.5).

Activity source · ChEMBL 36 via Core Engine
6 approved pChEMBL 10.5
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Nischarin matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q4G017, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

201
Total Compounds
21
Total Assays
6
Approved Drugs
IC50: 112.0, KI: 128.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL360803
 10.5 Ki —
No preferred name
CHEMBL2058635
 9.8 Ki —
No preferred name
CHEMBL3408293
 9.7 Ki —
No preferred name
CHEMBL13881
 9.3 Ki Clinical
No preferred name
CHEMBL2058631
 9.0 Ki —

Approved Drugs

Structure Compound First Approval
LOFEXIDINE
CHEMBL17860
 2018
MOXONIDINE
CHEMBL19236
 1991
RILMENIDINE
CHEMBL289480
 1987
CLONIDINE
CHEMBL134
 1974
NAPHAZOLINE
CHEMBL761
 1971
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:28Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5221